Current Report Filing (8-k)
July 21 2017 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
July 21, 2017
Bionik
Laboratories Corp.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
|
|
000-54717
|
|
27-1340346
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (416) 640-7887
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
|
Item 5.02
|
Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers.
|
As of July 21, 2017,
Hermano Igo Krebs, a director of Bionik Laboratories Corp. (the “Company”), resigned from the Board of Directors of
the Company (the “Board”). Mr. Krebs expressed to the Board that he is not in agreement with the strategy and execution
by the Company.
|
Item 9.01
|
Financial Statements and
Exhibits.
|
Exhibit
|
|
Description
|
99.1
|
|
Written correspondence by Hermano Igo Krebs
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: July 21, 2017
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Peter Bloch
|
|
|
Name:
|
Peter Bloch
|
|
|
Title:
|
Chief Executive Officer
|
|
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Apr 2023 to Apr 2024